Skip to main content

Advertisement

Table 1 Demographics and clinicopathologic parameters for the 33 mucinous ovarian carcinoma cases identified retrospectively.

From: HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

Parameter   HER2+ HER2- p-value
Age (years)   48.0 (31-72) 51.4 (18-76) 0.62a
Stage I 67% (N = 4) 67% (N = 18) 0.88b
  II 33% (N = 2) 29% (N = 8)  
  III 0% (N = 0) 4% (N = 1)  
Grade 1 50% (N = 3) 30% (N = 8) 0.55b
  2 50% (N = 3) 63% (N = 17)  
  3 0% (N = 0) 7% (N = 2)  
Residual Disease No 100% (N = 6) 100% (N = 27) NR
Prior Chemotherapy No 100% (N = 6) 100% (N = 27) NR
Mean Progression Free Survival (years)   7.90 (3.20 -- 11.35) 5.15 (0.17 -- 20.4) 0.12a
Mean Overall Survival (years)   7.90 (3.20 -- 11.35) 5.43 (0.35 -- 20.4) 0.16a
  1. Progression free survival (PFS) is defined as the time from surgery to the first clinical evidence of recurrence. Overall survival (OS) is defined as the time from surgery until death from any cause, or until the date of last follow-up. All times are given in years
  2. a Comparisons across HER2 status computed with the Welch ANOVA test
  3. b Comparisons across HER2 status computed with the Pearson Chi Square Statistic
  4. NR Not reported due to equivalence